CT-388
Roche Continues to Reap Rewards of Carmot Buyout with Strong Early GLP-1 Data
Roche, Carmot Therapeutics, GLP-1/GIP receptor agonist, CT-388, obesity treatment, weight loss, diabetes, pharmaceutical industry
Actionable Insights Powered by AI
Roche, Carmot Therapeutics, GLP-1/GIP receptor agonist, CT-388, obesity treatment, weight loss, diabetes, pharmaceutical industry